Literature DB >> 32292553

Design and Synthesis of Benzene Congeners of Resolvin E2, a Proresolving Lipid Mediator, as Its Stable Equivalents.

Yuto Murakami1, Hayato Fukuda1,2, Ryuta Muromoto1, Koki Hirashima1, Kohei Ishimura1, Koichi Fujiwara1, Jun Ishihara2, Tadashi Matsuda1, Mizuki Watanabe1, Satoshi Shuto1,1.   

Abstract

Resolvins (Rvs) are highly potent anti-inflammatory lipid mediators that are chemically and biologically unstable because of their polyunsaturated structures. To address this issue, we designed benzene congeners of RvE2, i.e., o-, m-, and p-BZ-RvE2s, as stable equivalents of RvE2 by replacing the unstable skipped diene moiety with a benzene ring on the basis of computational conformation studies and synthesized these congeners via a short common route through two Stille couplings. o-BZ-RvE2 exhibited more potent anti-inflammatory activity and much higher metabolic stability than RvE2. Thus, o-BZ-RvE2 was identified as a stable equivalent of RvE2, which is useful as a lead for anti-inflammatory drugs with a new mechanism of action as well as a biotool for investigating RvE2-mediated inflammation resolving pathways.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32292553      PMCID: PMC7153029          DOI: 10.1021/acsmedchemlett.9b00596

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

1.  Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1.

Authors:  Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

Review 2.  Free radical lipid peroxidation: mechanisms and analysis.

Authors:  Huiyong Yin; Libin Xu; Ned A Porter
Journal:  Chem Rev       Date:  2011-08-23       Impact factor: 60.622

Review 3.  Resolvins and protectins in inflammation resolution.

Authors:  Charles N Serhan; Nicos A Petasis
Journal:  Chem Rev       Date:  2011-07-18       Impact factor: 60.622

4.  Different pro-inflammatory and immunogenic potentials of Propionibacterium acnes and Staphylococcus epidermidis: implications for chronic inflammatory acne.

Authors:  Anna Białecka; Monika Mak; Rafał Biedroń; Małgorzata Bobek; Andrzej Kasprowicz; Janusz Marcinkiewicz
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2005 Jan-Feb       Impact factor: 4.291

Review 5.  Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs.

Authors:  Ingvar Bjarnason; Carmelo Scarpignato; Erik Holmgren; Michael Olszewski; Kim D Rainsford; Angel Lanas
Journal:  Gastroenterology       Date:  2017-12-06       Impact factor: 22.682

Review 6.  Prostaglandins and inflammation.

Authors:  Emanuela Ricciotti; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05       Impact factor: 8.311

7.  The use of phosphine ligands to control the regiochemistry of Pd-catalyzed hydrostannations of 1-alkynes: synthesis of (E)-1-tributylstannyl-1-alkenes.

Authors:  Alla Darwish; Adam Lang; Thomas Kim; J Michael Chong
Journal:  Org Lett       Date:  2008-02-01       Impact factor: 6.005

8.  Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity.

Authors:  R Z Ananias; E G Rodrigues; E G Braga; C C Squaiella; J S Mussalem; A L F Longhini; L R Travassos; I M Longo-Maugéri
Journal:  Scand J Immunol       Date:  2007-06       Impact factor: 3.487

9.  Resolvin D2 Induces Resolution of Periapical Inflammation and Promotes Healing of Periapical Lesions in Rat Periapical Periodontitis.

Authors:  Yasir Dilshad Siddiqui; Kazuhiro Omori; Takashi Ito; Keisuke Yamashiro; Shin Nakamura; Kentaro Okamoto; Mitsuaki Ono; Tadashi Yamamoto; Thomas E Van Dyke; Shogo Takashiba
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

10.  Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections.

Authors:  Jesmond Dalli; Nan Chiang; Charles N Serhan
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

View more
  5 in total

Review 1.  Specialized pro-resolving mediator network: an update on production and actions.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Essays Biochem       Date:  2020-09-23       Impact factor: 8.000

2.  Synthesis of Resolvin E1 and Its Conformationally Restricted Cyclopropane Congeners with Potent Anti-Inflammatory Effect.

Authors:  Kohei Ishimura; Hayato Fukuda; Koichi Fujiwara; Ryuta Muromoto; Koki Hirashima; Yuto Murakami; Mizuki Watanabe; Jun Ishihara; Tadashi Matsuda; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2021-01-21       Impact factor: 4.345

3.  A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution.

Authors:  Stephania Libreros; Ashley E Shay; Robert Nshimiyimana; David Fichtner; Michael J Martin; Nicholas Wourms; Charles N Serhan
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

4.  Stereoselective Synthesis and Structural Confirmation of the Specialized Pro-Resolving Mediator Resolvin E4.

Authors:  Amalie Føreid Reinertsen; Karoline Gangestad Primdahl; Ashley Elizabeth Shay; Charles Nicholas Serhan; Trond Vidar Hansen; Marius Aursnes
Journal:  J Org Chem       Date:  2021-02-03       Impact factor: 4.354

Review 5.  E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.

Authors:  Charles N Serhan; Stephania Libreros; Robert Nshimiyimana
Journal:  Semin Immunol       Date:  2022-02-16       Impact factor: 11.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.